[Cardiogenic shock in acute myocardial infarction--what we know in 2005].
Jan Vojáček, Bis J
Abstract
Jan Vojáček, Bis J
Abstract
Cardiogenic shock represents a complication in up to 10% of patients with acute myocardial infarction. Cardiogenic shock mortality remains high. In the contemporary treatment inhibitors of NO synthase are studied, apart from classic medications. Mechanical circulatory support is also important in majority of patients with cardiogenic shock: intraaortic balloon contrapulsation, left ventricular assist device systems. Prognosis is improved by percutaneous coronary intervention.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Cardiogenic shock represents a complication in up to 10% of patients with acute myocardial infarction. Cardiogenic shock mortality remains high. In the contemporary treatment inhibitors of NO synthase are studied, apart from classic medications. Mechanical circulatory support is also important in majority of patients with cardiogenic shock: intraaortic balloon contrapulsation, left ventricular assist device systems. Prognosis is improved by percutaneous coronary intervention.
Key concepts: Cardiogenic shock, Myocardial infarction, Medicine, Cardiology, Internal medicine, Shock (circulatory), Circulatory system, Complication